Other income rescues profits of early birds; operating margins of 164 firms shrink in Q2

The earnings season has got off to a subdued start, with virtually every heavyweight disappointing the Street. Net profits of a sample of 164 companies (including banks and financials) were up 7% year-on-year on the back of an 8% rise in revenues. But net profits would have fallen but for a 23% jump in other income.

The across-the-board miss in estimates suggests the Street has been unable to gauge the extent of sluggishness in demand, whether for IT services or for consumer goods. Among the reasons the managements have attributed to the indifferent numbers include muted consumer demand, elevated commodity prices and higher advertising and promotion spends amidst competitive intensity.

Also, some businesses were disrupted by heavy rains this season. Demand so far in the festive season has been low. For the sample companies, operating margins have contracted 63 basis points (bps).

Also Read Companies make a beeline to set up RE storage capacities FIIs continue to pummel markets RE targets can swell solar import bill to $30 billion a year Central Bank of India’s PAT jumps 51 per cent to Rs 913 crore

At Avenue Supermarts, the growth in same-store-sales (for stores that are of two years or older) decelerated to 5.5% from 9.1% in Q1FY25. The management attributed the deceleration to heightened competition from quick-commerce companies. The subdued rise in revenues resulted in a contraction in the Ebitda (earnings before interest, tax, depreciation and amortisation) margin of 40 basis points and a muted 10.3% increase in operating profits. Nestle reported poor volumes which fell 2% and weak domestic sales growth of just 1.2%, a big miss. The company’s Ebitda margin fell by 140 bps missing estimates and leaving the Ebitda growth at sub 5%.The management has attributed this to muted consumer demand and elevated commodity prices. 

Also ReadKotak Mahindra Bank reports 5% rise in standalone net profit

Although Havells was able to grow revenues by a strong 16.5%, higher costs pushed down margins by 120 bps. Bajaj Auto’s net revenues came in below estimates with the average selling prices coming in lower than those pencilled in.  The product mix has been inferior for both the local and export markets. Gross margins were weak and analysts estimate that, adjusted for productivity-linked incentive benefits,

 » Read More

Related Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Stay Connected

0FansLike
0FollowersFollow
0SubscribersSubscribe
- Advertisement -

Latest Articles

Trump tariff impact: Pharma stocks surge over 4% on tariff exemption

It’s a party for pharma stocks on Dalal Street. The Nifty Pharma Index is up nearly 4% and Sun Pharma, Gland Pharma and IPCA Labs see gains close to 4% each. Even Lupin and Natco Pharma are rallying smartly. In a major relief, Indian pharmaceutical companies breathed a sigh of relief after US President Donald

Trump tariff impact: Tech stocks plummet, Nifty IT cracks 2.5%

The share price of IT stocks slumped after US President Donald Trump’s administration imposed 26% reciprocal tariffs on Indian imports to the US. The Nifty IT, a basket of Indian tech stocks, fell 2.5% to 35,371.55 levels.  All the constituents of the sectoral index were trading in the red. The share price of Persistent Systems

Trump tariffs send shockwaves across global markets; US futures crash, gold soars to new highs- 10 cues you need to track now

Indian stock markets are set for a turbulent start as global jitters over Trump’s new tariffs weigh on. Early trends from GIFT Nifty point to a sharp drop of over 350 points, signaling a weak opening for Sensex and Nifty 50. Indian stock markets ended on a positive note in the previous trading session, with

‘Pramerica Life targets Rs 3,000-crore GWP in FY26,’ Pankaj Gupta

Pramerica Life Insurance, a joint venture between subsidiaries of Piramal Capital and Housing Finance and US-based Prudential Financial Inc, aims to close FY26 with Rs 3,000 crore in gross written premium. In an interview with Narayanan V, managing director and CEO Pankaj Gupta discusses the products and distribution strategy. Excerpts: Life insurance premiums have been

Tata small cap fund: Targeting growth at reasonable valuations

Tata Small Cap Fund is a growth-oriented scheme in the Small Cap Fund category that has exhibited a noteworthy track record since its inception and has outpaced many of its prominent peers, thereby rewarding investors with superior risk-adjusted returns. Launched in November 2018, Tata Small Cap Fund aims to invest in stocks of companies that are in growth